Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Documenti analoghi

• Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real‐World Multicenter Retrospective Study
  di: Ryuma Tanaka, et al.
  Pubblicazione: (2026)
• Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real‐World Multicenter Study
  di: Kai Ozaki, et al.
  Pubblicazione: (2025)
• Enfortumab Vedotin–Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding
  di: Aika Matsuyama, et al.
  Pubblicazione: (2025)
• Impact of C‐Reactive Protein Kinetics on the Prognosis of the Patient With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin
  di: Hiroki Tsujioka, et al.
  Pubblicazione: (2025)
• Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
  di: Siming Li, et al.
  Pubblicazione: (2024)